Pharmaceutical ERA•Regulatory Toxicology•PDE / OEL
[email protected]
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Amitriptyline→

Amitriptyline Environmental Risk Assessment (ERA)

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50-48-6
Molecular formula
C20H23N
Molecular weight
277.4 g/mol

Chemical identifiers are reproduced from the ToxWriter API catalogue for reference. Confirm the substance identity and relevant form, including any salt, hydrate or isomer, against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental risk assessment (ERA)

ToxWriter provides environmental risk assessment support for human medicinal products. The assessment may include regulatory exposure screening and, where indicated, further evaluation of environmental fate and effects. Scope is defined by the medicinal product, substance form, route of administration, intended market and available environmental evidence.

ERA services may include

  • Review of product details, substance form, route, use pattern and intended market.
  • Phase I environmental exposure screening under the applicable regulatory framework.
  • Phase II environmental fate and ecotoxicity assessment where indicated by the pathway and evidence.
  • PEC/PNEC risk characterisation, PBT/vPvB review and data-gap analysis where relevant.
Assessment considerations

Factors that determine the assessment scope

The applicable ERA pathway is determined by the product and its use, the requirements of the intended market and the environmental data available for review.

  • Exact active-substance form and product identity.
  • Route, maximum daily dose and use assumptions, where applicable.
  • Intended markets and available environmental data or studies.
Assessment deliverablesThe agreed report presents the assessment pathway, supporting evidence, assumptions, uncertainties and conclusions for the defined product and market.
ERA regulatory framework
ERA background →EMA environmental risk assessment guideline · EU human medicinesMHRA environmental risk assessments in medicines · UK

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.